DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE: A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/pm84fx67Keywords:
CKD, treatment, diabetes mellitusAbstract
Background: The increase in type 2 diabetes has positioned it as the leading cause of chronic kidney disease (CKD) and is responsible for approximately half of all cases of end-stage kidney disease (ESKD) worldwide. Managing CKD in diabetic patients entails addressing its complications and minimizing the risk of other associated conditions, such as cardiovascular disease. This study aims to serve a comprehensive systematic review on diabetes management in CKD patients in literatures of the last 10 years.
Methods: The systematic review followed PRISMA 2020 standards and examined full-text English literature published between 2014 and 2024. This review excluded editorials, review papers from the same journal, and submissions without a DOI. Literature was sourced from online platforms such as PubMed, SagePub, SpringerLink, and Google Scholar.
Result: A total of 43,740 articles were retrieved from online databases (PubMed, SagePub, SpringerLink and Google Scholar). After three rounds of screening, four articles directly relevant to the systematic review were selected for fulltext reading and analysis.
Conclusion: Chronic kidney disease (CKD) is a common and serious complication in individuals with diabetes. Management involves controlling hypertension and hyperglycemia, along with using ACE inhibitors like finerenone and SGLT2 inhibitors such as dapagliflozin, sotagliflozin, and bexagliflozin.
References
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1–127.
Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocrine Reviews [Internet]. 2020 Oct 1 [cited 2024 Mar 11];41(5):756–74. Available from: https://doi.org/10.1210/endrev/bnaa017
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care [Internet]. 2022 Oct 3 [cited 2024 Mar 11];45(12):3075–90. Available from: https://doi.org/10.2337/dci22-0027
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–29.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med [Internet]. 2020 Oct 8 [cited 2024 Mar 11];383(15):1436–46. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2024816
Škrtić M, Cherney DZI, Sridhar VS, Chan CTM, Kitchlu A. SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus Post-Nephrectomy: A Single-Center Case Series. Can J Kidney Health Dis [Internet]. 2021 Jan 1 [cited 2024 Mar 11];8:20543581211065528. Available from: https://doi.org/10.1177/20543581211065528
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine [Internet]. 2021 Jan 14 [cited 2024 Mar 11];384(2):129–39. Available from: https://doi.org/10.1056/NEJMoa2030186
Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. Am J Kidney Dis. 2019 Sep;74(3):328–37.
Kelepouris E, St. Peter W, Neumiller JJ, Wright EE. Optimizing Multidisciplinary Care of Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. Diabetes Ther [Internet]. 2023 Jul 1 [cited 2024 Mar 11];14(7):1111–36. Available from: https://doi.org/10.1007/s13300-023-01416-2
Li J, Du D, Zhang J, Liu W, Wang J, Wei X, et al. Development and validation of an artificial intelligence-powered acne grading system incorporating lesion identification. Front Med (Lausanne) [Internet]. 2023 Oct 6 [cited 2024 Mar 5];10:1255704. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587552/
Shishido T, Ono Y, Kumazawa I, Iwai I, Suzuki K. Artificial intelligence model substantially improves stratum
corneum moisture content prediction from visible-light skin images and skin feature factors. Skin Research and Technology [Internet]. 2023 [cited 2024 Mar 5];29(8):e13414. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/srt.13414
Anqi S, Xiukun S, Ai’e X. Quantitative evaluation of sensitive skin by ANTERA 3D® combined with GPSkin Barrier®. Skin Research and Technology [Internet]. 2022 [cited 2024 Mar 5];28(6):840–5. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/srt.13213
Shen X, Zhang J, Yan C, Zhou H. An Automatic Diagnosis Method of Facial Acne Vulgaris Based on Convolutional Neural Network. Sci Rep [Internet]. 2018 Apr 11 [cited 2024 Mar 5];8(1):5839. Available from: https://www.nature.com/articles/s41598-018-24204-6
Lee J, Yoon H, Kim S, Lee C, Lee J, Yoo S. Deep learning-based skin care product recommendation: A focus on cosmetic ingredient analysis and facial skin conditions. Journal of Cosmetic Dermatology [Internet]. 2024 Jan 25 [cited 2024 Mar 7];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.16218
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
